Drug Type Trispecific T-cell engager (TriTE) |
Synonyms |
Target |
Action inhibitors, stimulants |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CD8 stimulants(Cluster of differentiation 8 stimulants) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| B-Cell Lymphoma | Preclinical | China | 22 Mar 2024 | |
| B-Cell Leukemia | Preclinical | China | - | |
| CD20 Positive B-Cell Non-Hodgkin Lymphoma | Preclinical | China | - |






